- United States
- /
- Medical Equipment
- /
- NasdaqCM:NAOV
NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)
NanoVibronix (NASDAQ:NAOV) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$376.0k (down 18% from 3Q 2023).
- Net loss: US$998.0k (loss widened by 37% from 3Q 2023).
- US$0.36 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
NanoVibronix shares are down 1.5% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with NanoVibronix (at least 3 which are significant), and understanding them should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if NanoVibronix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NAOV
NanoVibronix
Through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally.
Moderate with adequate balance sheet.